Amneal Pharmaceuticals, Inc.

NasdaqGS:AMRX

Market Cap

USD 3.71 B

Share Price

USD 7.91

Avg Daily Volume

1,882,950

Change (1 day)

-0.75%

Change (1 year)

9.25%

Change (YTD)

-0.13%

Amneal Pharmaceuticals, Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending March 31, 2025: 19.99%

Amneal Pharmaceuticals, Inc. EBITDA Margin is 19.99% for the Trailing 12 Months (TTM) ending March 31, 2025, a -8.93% change year over year. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.
  • Amneal Pharmaceuticals, Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending March 31, 2024 was 21.95%, a 134.53% change year over year.
  • Amneal Pharmaceuticals, Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending March 31, 2023 was 9.36%, a -53.85% change year over year.
  • Amneal Pharmaceuticals, Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending March 31, 2022 was 20.28%, a 12.49% change year over year.
  • Amneal Pharmaceuticals, Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending March 31, 2021 was 18.03%, a 15.87% change year over year.
Key Data
Date EBITDA Margin Net Income Margin EBT Margin Operating Income Margin